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Current Opinion 
Portal hypertension is characterized by a rise in portal
venous pressure and the formation of portosystemic collat-
erals, which divert the blood to the portosystemic circu-
lation. The measure of free and wedged hepatic venous
pressures and the gradient between these two pressures—
the hepatic venous pressure gradient (HVPG)—is a method
that appears to reflect portal pressure accurately and reli-
ably. In normal individuals, HVPG varies from 1 to
5 mmHg. If HVPG is above these levels, then portal hyper-
tension is considered to exist.1 Clinically significant portal
hypertension is defined by HVPG above 12 mmHg. In
patients with chronic liver disease, HVPG above 12 mmHg
is related to the development of oesophageal varices, risk
of variceal bleeding and development of ascites.1
Measurement of HVPG is a common and indirect way
of assessing the portal pressure gradient in cirrhotic
patients with a predominantly sinusoidal site of resist-
ance. Baseline and repeated measurement of HVPG have
been recommended for the management of patients with
cirrhosis in the setting of pharmacological prophylaxis of
variceal bleeding.
It has been shown that prophylaxis with beta-blockers
decreases the risk of first variceal bleeding in cirrhotic
patients with portal hypertension and oesophageal varices
at risk of bleeding. The addition of long-acting nitrates
has been shown to enhance the efficacy of beta-blockers.
Pharmacotherapy decreases the risk of variceal bleeding
by half or three-fourths, but does not abolish the risk of
bleeding totally.2 Therefore, it is important to distinguish
between patients who will benefit from treatment and
those who will not, and who may be eligible for addition
of other prophylactic treatments such as endoscopic 
band ligation. Such a subgroup of patients should be
identified and can be offered alternative treatments. 
It is useful to know the factors predicting clinical
response or non-response to treatment so that non-
responders can be identified and managed with other
modes of treatment.
In earlier studies, non-selective beta-blocker dose 
was empirical (i.e., to the maximum tolerated by the
patient or to the reduction of the resting pulse rate 
to 55/minute). In patients on drugs for prevention of
variceal bleeding, it has been shown that a decrease in por-
tal pressure expressed as a decrease in HVPG is a good pre-
dictor of clinical efficacy. Decrease in HVPG to 12 mmHg
or less or decrease by at least 20% of baseline values 
is associated with minimal risk of variceal bleeding.3 The
risk of variceal bleeding remains high in patients not
meeting these haemodynamic end points after drug ther-
apy. In a study by Groszmann et al, it was found that a
decrease in HVPG to 12 mmHg or less is a good predictor
of effective prophylaxis, but percentage variations do not
define any useful cut-off value.4 The clinical value of this
predictor was limited because the haemodynamic end
point was reached in less than one-fourth of patients,
whereas the other two-thirds were not bleeding. This pre-
diction rule was sensitive but not specific in predicting
failure of treatment. The prognostic value of a 20%
decrease in HVPG from baseline value was not assessed 
in this study.
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Acute variceal bleeding
It has been shown that early measurement of portal pres-
sure can provide useful prognostic information in cirrhotic
patients admitted because of acute variceal bleeding.
Increase in portal pressure is directly related to the tension
exerted on the walls of varices, which is considered to be
the main determinant of both variceal rupture and the
magnitude of bleeding. Such patients with higher portal
pressure are likely to have severe haemorrhage when they
are bleeding; also, their bleeding will be difficult to control
with a greater tendency for early rebleeding. The risk fac-
tor for failure of medical and endoscopic treatment of
acute variceal bleeding is HVPG.
Moitinho et al found that HVPG was the only variable
associated with the outcome of variceal bleeding, thereby
supporting the concept that degree of portal pressure
increase plays a key role in determining the magnitude of
bleeding, its response to emergency treatment and the
likelihood of early rebleeding.5 It was found that patients
with HVPG > 20 mmHg had a significantly increased risk
of failing first line treatment of acute variceal bleeding,
continued bleeding, early rebleeding and high mortality.
Patients with variceal bleeding who were found to have
HVPG > 20 mmHg had a 5.21-fold likelihood of emer-
gency treatment not controlling their bleeding or present-
ing with early rebleeding. These patients also required
significantly more blood transfusions, more days of 
stay in the ICU and hospital and showed higher morta-
lity on follow-up. HVPG monitoring in patients with
acute variceal bleeding may allow one to select high-risk
patients who require close surveillance and probably a
more aggressive therapeutic approach. Monescillo et al
reported the results confirming that a HVPG > 20 mmHg
is associated with poor outcome and thus this may be
used as a criterion for patients requiring ICU admission
in hospital.6 Monescillo et al assessed accuracy of HVPG
as a predictor of treatment failure in acute variceal 
bleeding.6 HVPG was measured in all patients within 24
hours of admission. Using a cut-off value of 20 mmHg, 
64 patients had HVPG below this value and were placed
into the low-risk category. The 52 patients with 
HVPG > 20 mmHg were deemed high risk. Treatment fail-
ure was defined as either failure to control acute bleeding
or rebleeding within 5 days of initial therapy. The primary
end point of the study was an assessment of HVPG cut-
off value of 20 mmHg as a predictor of treatment failure.
The sensitivity of HVPG of 20 mmHg as a predictor of
treatment failure was 62%, specificity 81%, positive pre-
dictive value 50% and negative predictive value 87%.
Multivariate analysis revealed HVPG > 20 mmHg and
Child-Turcotte Pugh (CTP) score as two independent 
predictors of treatment failure. HVPG was a significantly
better predictor of 6-week mortality than the CTP score.
Early measurement of HVPG reliably predicts treatment
failure and survival.
It has been argued that it is difficult to carry out emer-
gency HVPG measurement; however, now it has been shown
that HVPG measurement is a simple, safe and highly repro-
ducible procedure that does not take more than 20 minutes
to execute. Also it may guide on the use of HVPG monitor-
ing to assess the effects of therapy. In patients admitted 
with acute variceal bleeding who are found to have 
HVPG > 20 mmHg, reduction of HVPG below this thres-
hold by vasoactive drugs may improve the outcome.
Secondary prophylaxis
Recurrent variceal bleeding is very frequent after variceal
haemorrhage unless pharmacological or endoscopic ther-
apy is used for secondary prevention. Recently, baseline
and repeated measurement of HVPG have been consid-
ered necessary to optimally manage patients receiving
pharmacological therapy so as to reduce the frequency of
rebleeding by defining two targets: ≥ 20% reduction from
baseline HVPG and an absolute reduction to ≤ 12 mmHg.
Bureau et al reported the results of adapting medical ther-
apy to monitor HVPG response in the prevention of
variceal rebleeding in patients with cirrhosis.7 HVPG 
was measured before and after drug therapy was initiated.
Patients were considered to be responders if HVPG
decreased below 12 mmHg or by at least 20% as compared
to baseline value. Of 14 patients treated to prevent rebleed-
ing, two of the six responders bled as compared with
seven of the eight non-responders, even though all non-
responders were treated by variceal ligation. Therefore, it
is important to note that HVPG response can be used to
identify the patients who are not efficiently protected.
Long-term drug therapy is emerging as an effective
treatment for the prevention of variceal rebleeding. The
role of HVPG monitoring as a guide to identify patients
requiring further treatment needs to be evaluated further.
Trials to determine the best treatment for patients who
do not respond to drug therapy are also required.
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Longitudinal haemodynamic studies have shown that if
HVPG is decreased below the threshold value, then patients
will have a lower risk of variceal rebleeding (Table).
A randomized trial of endoscopic band ligation and
drug therapy versus endoscopic band ligation alone
reported a 23% risk of rebleeding within 2 years in the
combination group.13 This result is not better than the
results in responders to drug therapy as defined by HVPG
and has the disadvantage of increasing the cost and 
complications of endoscopic therapy.
Assessment of HVPG response will provide strong
prognostic information, since responders on HVPG crite-
ria do better than non-responders. HVPG assessment
should be done early as Patch et al have shown that the
risk of rebleeding is especially high during the first 6
weeks after the index haemorrhage.12 Others recommend
adding isosorbide mononitrate (ISMN) in all patients,
thus obviating the need to assess HVPG response. This
idea seems reasonable in high-risk situations such as the
prevention of recurrent bleeding. The best treatment for
a patient who does not respond to combination drug
therapy is unknown. If drug therapy is continued, the risk
of rebleeding will be high. With only endoscopic band 
ligation, the risk of rebleeding is also high, 88% at 2 years
in this group of patients. The low rate of rebleeding with
a combination of endoscopic band ligation and beta-
blockers suggests that endoscopic band ligation with con-
tinuation of beta-blockers may be an useful approach.
Targownik et al compared the cost effectiveness of
HVPG monitoring in the prevention of recurrent variceal
bleeding and found that compared to endoscopic band lig-
ation for the secondary prophylaxis of variceal rebleeding,
combination medical therapy guided by HVPG monitoring
was more effective and only marginally more expensive.14
Primary prophylaxis
Merkel et al assessed the role of haemodynamic response
to beta-blockers or beta-blockers plus nitrates in predicting
the clinical efficacy of prophylaxis in 49 cirrhotic patients
with varices at risk of bleeding but without prior variceal
bleeding.2 Hepatic vein catheterization was performed
before and after 1–3 months of treatment with nadolol 
or nadolol plus ISMN. A total of 30 patients (61%) were
good haemodynamic responders and among them, 12
(24%) had HVPG ≤ 12 mmHg, nine had variceal bleeding,
seven were poor responders and two were good responders
during treatment. The probability of bleeding at 3 years
of follow-up was significantly higher in poor responders
(41%) than in good responders (7%). The probability of
variceal bleeding was also higher in patients who had
HVPG during treatment higher than 12 mmHg (9/37, 
3-year risk of 28%) than in those who reached the threshold
value of 12 mmHg (0/12). None of the patients reaching
HVPG of 12 mmHg or less during treatment had variceal
bleeding during follow-up. It was also found that, similar
to the condition of prevention of rebleeding, a decrease in
HVPG by 20% or more was also a strong predictor of suc-
cess of prophylaxis. Sensitivity in predicting bleeding was
78% (7/9) and specificity was 70% (28/40). No difference
in variceal bleeding was observed in relation to the initial
value of HVPG. Poor haemodynamic response was found
to be the main factor predicting bleeding. It was found
that assessment of haemodynamic response to drugs in
terms of HVPG is the best predictor of efficacy of prophy-
laxis of variceal bleeding in patients treated with beta-
blockers or beta-blockers plus nitrates. The clinical value
of HVPG changes remained stable also when other con-
founding factors such as size of varices, presence of red
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Table. Risk of variceal rebleeding in responders versus non-responders on drug therapy
Reference N Drug Non-responders (%)
Rebleeding rate (%)
Responders Non-responders
Feu et al8 69 Propranolol 64 8 54.5
Escorsell et al9 47 Propranolol 62 6 44.8
Villanueva et al10 31 Nadolol + ISMN 55 7 47.0
Villanueva et al11 49 Nadolol + ISMN 49 16 66.6
Bureau et al7 34 Propranolol + ISMN 41 10 64.0
Patch et al12 26 Propranolol + ISMN 45–63 7–13 46–65
ISMN = isosorbide mononitrate.
weal marks or North Italian Endoscopic Club (NIEC) index
were taken into consideration. It was found that in the
prediction of effectiveness of treatment, the haemody-
namic response is much more useful than the initial size
of varices and the presence of red weal marks. According
to this study, it appears that good responders are at a neg-
ligible risk of bleeding (2/30, 6.6%), whereas poor respon-
ders have a rather high risk (7/29, 25%), which is similar
to that expected in untreated patients. This difference
appears more relevant if one considers that the two good
responders who bled had precipitating factors that prob-
ably contributed to bleeding, such as the need to with-
draw treatment due to side effects or the occurrence of
portal vein thrombosis.
Bureau et al reported results of adapting medical ther-
apy to the monitoring of haemodynamic response in the
prevention of first variceal bleeding in patients with cir-
rhosis.7 HVPG was measured before and after 8.8 ± 12.1
days (median 4, range 1–60) of propranolol being initi-
ated. Patients were considered to be responders if HVPG
decreased below 12 mmHg or by at least 20% as compared
to the baseline value. If patients were not responders,
ISMN was added and a third haemodynamic study was
performed after 17.1 ± 12.6 days (median 15.5, range 3–47)
of initiation of ISMN. Thereafter, patients were followed
up for a mean of 28.1 ± 18.8 months (median 24, range
1–96). Of 20 patients treated for the prevention of first
variceal bleed, 14 (70%) were responders, 10 (50%) to pro-
pranolol alone and 4 (20%) to the combination of propra-
nolol and ISMN. None of the responders had variceal
bleeding during the follow-up period whereas 2/6 non-
responders (10% of total and 33.3% of non-responders)
experienced variceal bleeding. Post-treatment HVPG was
significantly greater in patients who bled than in those
who did not bleed (21 ± 0 mmHg vs. 13.5 ± 4.8 mmHg).
Using multivariate analysis, only haemodynamic response
was found to have an independent predictive value for 
the risk of variceal bleeding. Bureau et al concluded that
haemodynamic response to drug therapy identifies
patients who are efficiently protected from variceal bleed-
ing as well as non-responders in whom an alternative
treatment should be considered.7
In a study by Escorsell et al, it was shown that HVPG
response closely correlated with the risk of variceal bleed-
ing on follow-up.9 Reducing HVPG by 20% or more was
associated with a very low risk of bleeding, only 7% at 3
years of follow-up and 0% when final HVPG was less than
12 mmHg. In contrast, the risk of variceal bleeding was
56% in HVPG non-responders. Achieving 20% reduction
in HVPG was highly sensitive (85%) and specific (97%) in
identifying patients who did not bleed during follow-up.
These results have led to the recommendation of assess-
ing portal pressure response whenever possible in high-
risk patients.
The data on using HVPG measurements during pri-
mary prophylaxis are quite consistent. If patients achieve a
haemodynamic response to pharmacological therapy, their
risk of bleeding during the next 2–3 years falls to about 5%.
If HVPG falls to ≤ 12 mmHg (about one-third of patients),
then the risk of bleeding is close to zero. In contrast, in
those who fail to respond, the risk of bleeding is 30–40%
over the same period of time. About 40–55% of patients
achieve a haemodynamic response with beta-blockers alone
and another 20–30% with the addition of nitrates.
In the setting of primary prophylaxis of variceal bleed-
ing, HVPG measurements in principle could change man-
agement in two ways: (i) addition of a second drug, and 
(ii) the use of endoscopic variceal band ligation.15 Merkel 
et al have shown that the cumulative risk of bleeding was
decreased from 29% in those receiving nadolol alone to
12% in those who received the combination of nadolol
and ISMN.16 This data suggest that HVPG can guide the
decision to add nitrates to the pharmacological treatment
of portal hypertension. Combination therapy with beta-
blockers and nitrates should be restricted to patients
selected on the basis of failure to respond to beta-block-
ers. HVPG measurement may be used to guide the selec-
tion. The second way in which management strategy
could be influenced by HVPG measurement concerns the
use of endoscopic variceal band ligation. Several studies
have shown that band ligation is superior to no treatment
for primary prophylaxis of variceal bleeding and one has
found it superior to beta-blockers.9,15 HVPG measure-
ment can identify the subgroup of patients who do not
meet the haemodynamic criteria for success with beta-
blockers or beta-blockers plus ISMN therapy and who
might, therefore, benefit from band ligation.
Non-bleeding complications
The complications of cirrhosis, such as ascites, hepato-
renal syndrome or hepatic encephalopathy, are also related
to portal hypertension. There is very little data on the
assessment of long-term maintenance of haemodynamic
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response to the pharmacological treatment of portal
hypertension and the influence of such a response on
complications of cirrhosis other than variceal bleeding.
An increase in the portal pressure gradient to a threshold
of above 10–12 mmHg has also been established for the
development of ascites. When reduction below this target
is not achieved, a substantial decrease in portal pressure
(< 20% from the baseline value) also has a great impact 
on the development of ascites and other complications.
Villanueva et al reported that haemodynamic responders
have lower incidence of rebleeding from oesophageal
varices and lower treatment failures.17 The probability of
developing or worsening of ascites was significantly lower
in responders than in poor responders. During follow-
up, hepatorenal syndrome and spontaneous bacterial 
peritonitis developed more often in poor responders. The
likelihood of developing at least one episode of hepatic
encephalopathy during follow-up was lower in responders.
Among patients without previous episodes, encephalo-
pathy occurred more frequently in poor responders. On 
follow-up, the improvement in CTP score was greater in
responders and the possibility of requiring orthotopic
liver transplantation was lower in responders. The likeli-
hood of survival was also higher in responders. In another
study, Abraldes et al evaluated whether achieving haemo-
dynamic targets prevents complications of portal hyper-
tension and improves long-term survival.18 Over an 8-year
follow-up, it was found that non-responders had a signi-
ficantly higher risk of developing variceal rebleeding,
ascites, spontaneous bacterial peritonitis, hepatorenal
syndrome and hepatic encephalopathy than responders.
On multivariate analysis, being a non-responder was inde-
pendently associated with the risk of developing rebleed-
ing, ascites, spontaneous bacterial peritonitis and lower
survival.
Haemodynamic studies are usually considered inva-
sive. However, in a sample of 1,000 patients with liver dis-
ease undergoing transjugular liver biopsy, it was reported
that complications were related to liver biopsy itself and
not to the catheterization of hepatic veins.7
There is an issue of ideal timing of the control of haemo-
dynamic response to treatment: too early and the number
of responders will be underestimated; too late and patients
who have experienced bleeding episodes will be excluded.
The interval between two haemodynamic measurements
should be shortened as much as possible to permit assess-
ment of all patients and to avoid the problem of bleeding in
patients before the second haemodynamic assessment.
Merkel et al suggested 1 month to be the optimal time inter-
val between two haemodynamic assessments.2
However, the key issue is whether target reduction of
portal pressure, which involves a baseline and a repeated
HVPG measurement, is necessary in routine clinical prac-
tice. It significantly adds to the cost of pharmacotherapy,
is not universally available and several issues regarding its
use are still not clear.19,20 Unrecognized notable hetero-
geneity has been demonstrated in intrahepatic vasculature
and HVPG measurements in cirrhosis. The presumption
of interposition of non-flowing blood between the
catheter tip and the portal system for the measurement of
HVPG may be violated in about one-third of cirrhotic
cases because of abnormal outlet into hepatic venous
shunts and in a minor fraction because of abnormal arte-
rial inlet.21 Sixty percent of cirrhosis patients have shown
larger intrahepatic variations among HVPG measure-
ments performed in separate hepatic veins that could 
be attributed to technical and physiological variations.21
Also, there are some problems with the interpretation of
data on HVPG monitoring, clinical validity and applica-
bility, which make its use controversial. The cumulative
data raise a question: should HVPG measurement be used
routinely to follow patients receiving pharmacological
treatment for primary prophylaxis? Invasive intervention
should be performed only if the data obtained substan-
tially affect management strategy. The cost-effectiveness
of measuring HVPG response to medical treatment in
patients undergoing primary prophylaxis has been ques-
tioned. The cost can easily be evaluated but the effective-
ness is related to the efficacy of alternative treatment in
patients classified as poor responders. HVPG measure-
ment to guide primary prophylaxis has been found to be
an expensive strategy for reducing variceal bleeding or
death, especially in patients with limited life expectancy
such as advanced decompensated cirrhosis.22
Identifying the effective dose of beta-blockers for each
patient by assessing the haemodynamic response “step by
step” would require too many measurements and is incom-
patible with clinical practice. Also, in primary prevention,
the low bleeding rate (≤ 20%) and the protection offered by
non-selective beta-blockers do not justify HVPG monitor-
ing, particularly with invasive procedure. Moreover, the
cost-effectiveness of this approach has been questioned.22
HVPG measurement is safe and relatively simple. The
information obtained may be predictive for the occurrence
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of first variceal bleeding and can potentially help in deter-
mining whether pharmacological therapy is effective or
not.17 We need a safe and accurate noninvasive method
for the measurement of portal pressure. Until that goal 
is achieved, HVPG measurement remains the only way 
to assess responses to pharmacological therapy and to
develop a tailored approach to prevent variceal bleeding
in patients with portal hypertension.
The question that arises is, to what extent is the better
outcome of responders due to reduction in portal pres-
sure, and does the lack of response reflect more advanced
liver disease? It has been found that lack of response is
indeed a major determinant of worse prognosis seen in
non-responders as compared with responders. On multi-
variate analysis, lack of haemodynamic response has been
found to be an independent predictor of worse outcome
in terms of rebleeding, development of ascites, sponta-
neous bacterial peritonitis and survival. However, multi-
variate analysis has selected other additional variables
influencing prognosis. These variables are albumin, biliru-
bin and prothrombin ratio, which are clearly related to the
degree of liver failure. Therefore, both severity of liver dis-
ease and HVPG response are major independent determi-
nants of prognosis in patients with advanced liver disease
receiving pharmacological therapy for portal hypertension.
For primary prophylaxis of variceal bleeding, drug
therapy is initiated with oral propranolol twice a day.
Adjustment of the dose is done by stepwise increases,
carefully looking at clinical tolerance, heart rate and arte-
rial blood pressure. The dose is increased every 2 days
until the heart rate decreases by 25% of the baseline value
but not below 55 beats/minute. Other methods to assess
the response to drugs have been investigated, namely
Doppler ultrasonography, direct variceal pressure meas-
urement, variceal pressure measurement using pressure
gauge, plethysmography and serum catecholamine levels.
Doppler ultrasonography has unequivocally been shown
to be unreliable. Doppler ultrasound as a noninvasive 
standard has not been substantiated by prospective studies
and has limitations due to its relatively large variability and
observer dependency. The studies assessing accuracy of
Doppler ultrasonography in predicting HVPG response 
to use of beta-blockers alone or associated with ISMN
show discouraging results. Variceal pressure measurement 
by venous puncture through endoscopy is actually an
invasive technique and it must be followed by variceal
sclerotherapy or ligation; therefore, it is not a suitable
technique for repeated measurements. A gauge to meas-
ure variceal pressure has been designed but is available 
in only very few centres and can only be used with 
large varices and should be considered as an experimental
procedure.
Escorsell et al showed that the measurement of
variceal pressure using pressure gauge during diagnostic
endoscopy represents a noninvasive method to predict
clinical response to drug therapy for patients with portal
hypertension.9 A fall in variceal pressure of more than
20% from the baseline value was associated with very low
risk of variceal bleeding on follow-up. After achieving
such a response, the actual probability of variceal bleeding
was only 7% at 3 years, whereas it was 46% in patients 
failing to achieve this target, despite receiving the same
therapy. The predictive value of 20% or more decrease 
in variceal pressure is likely to be related to the fact that 
it determines a marked fall in variceal wall tension, which
is a major determinant of bleeding. It was shown that
variceal pressure and HVPG response to drug therapy were
the only independent predictors of variceal bleeding on
follow-up. Measurement of variceal pressure response
and HVPG response is complementary because some
variceal pressure responders are not HVPG responders
and vice versa. This can be due to variability of variceal
pressure measurement and reflection of slightly different
haemodynamic events by these measurements. It has been
shown that in some patients, propranolol causes a more
pronounced decrease in gastroesophageal collateral blood
flow and variceal pressure than in hepatic blood flow 
and HVPG.
Recommendations
1. In patients with cirrhotic liver without prior variceal
bleeding with oesophageal varices at high risk of bleed-
ing (large oesophageal varices [grade III or IV], pres-
ence of red colour signs on varices), if beta-blocker
therapy is contemplated, HVPG measurement is 
recommended. 
2. After HVPG measurement, beta-blocker (propranolol)
is started as 20 mg twice a day and a stepwise increase
in dose is made every 2 days until a maximum toler-
ated dose is reached or the reduction in heart rate to
55 beats/minute is achieved.
3. HVPG measurement is to be repeated 1 month after
achieving adequate beta-blockage.
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4. Assessment of response: HVPG decrease ≤ 12 mmHg 
or decrease by at least 20% of baseline value.
(a) Responder (yes): continue same dose of beta-
blockers.
(b) Non-responder (no): add ISMN.
5. In patients non-responsive to beta-blockers and receiv-
ing a combination of beta-blockers and ISMN, repeat
HVPG measurement is recommended 1 month after
addition of ISMN.
6. Assessment of response: HVPG decrease ≤ 12 mmHg
or decrease by at least 20% of baseline value.
(a) Responder (yes): continue the combination of beta-
blockers and ISMN in the same doses.
(b) Non-responder (no): recommendations are:
– In clinical practice: endoscopic band ligation of
oesophageal varices for primary prophylaxis.
– In research protocols: addition of other drugs
such as carvedilol or prazosin and repeat HVPG
measurement 1 month after addition of the new
drugs.
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